Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Appropriate Evaluation of Antiviral Therapy With Nirmatrelvir-ritonavir in Hospitalized Patients: a Multicenter Retrospective Study in China

ID
Name
AEATN
Description
The primary objective of the study was to assess the appropriateness of antiviral therapy with nirmatrelvir-ritonavir in hospitalized patients.
Trial arms
Trial start
2022-12-15
Estimated PCD
2023-04-01
Trial end
2023-04-01
Status
Recruiting
Treatment
Nirmatrelvir-Ritonavir
Nirmatrelvir-Ritonavir
Arms:
Nirmatrelvir-Ritonavir
Other names:
PAXLOVID
Size
200
Primary endpoint
The prevalence of inappropriate use of nirmatrelvir-ritonavir
baseline
Eligibility criteria
Inclusion Criteria: * hospitalized patients receiving at least one dose nirmatrelvir-ritonavir Exclusion Criteria: * None
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 200, 'type': 'ESTIMATED'}}
Updated at
2023-03-01

1 organization

1 product

1 indication

Organization
First People's Hospital of Hangzhou
Product
Nirmatrelvir-Ritonavir
Indication
Hospitalized Patients